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Abstract 
Chronic inflammation and airway remodeling are characteristics of chronic obstructive pulmonary 
disease (COPD). Abnormalities in hyaluronic acid, a component of the extracellular matrix, may be 
involved in the pathogenesis of COPD. But there are no researchers about its role like a marker of 
effectiveness of anti-inflammatory therapy (AIT) at patients with COPD. 
The study is devoted to the diagnostic value of HA at patients with COPD, the role of the HA as a marker 
of the effectiveness of AIT at patients with COPD. 
It was determined that the level of HA at patients with COPD before AIT was significantly higher than it 
at patients of the control group. But in 3 months after correction of treatment the level of HA decreased 
significantly at all patients comparing to previous visit, which corresponded to the level of the control 
group. 
It means that the significant decreasing of HA level at patients with COPD may be a marker of the 
effectiveness of AIT. 
 
Keywords: chronic obstructive pulmonary disease, systemic inflammation, pulmonary fibrosis, 
hyaluronic acid. 
 
1. Introduction  
Hyaluronic acid (HA) (also called haluronan or hyaluronate) is an anionic, nonsulfated 
glycosaminoglycan (GAG) distributed widely throughout connective, epithelial, and neural 
tissues [1]. 
Abnormalities in hyaluronic acid, a component of the extracellular matrix, may be involved in 
the pathogenesis of asthma and chronic obstructive pulmonary disease (COPD), in vitro 
research indicates [2]. Chronic inflammation and airway remodelling are characteristics of 
COPD [3].  
The study, conducted by an international research team, focused on the expression of 
glycosaminoglycans (GAGs) and their metabolizing enzymes in primary human airway 
smooth muscle cells (ASMC) [4]. GAGs are essential constituents of the extracellular matrix in 
the lung and play a key role in regulating tissue flexibility [2]. 
Other research indicate a relationship between HA levels, local inflammation and severity of 
disease, and suggest enhanced breakdown of HA in the lungs of patients with COPD. HA is an 
extracellular matrix compound with proinflammatory activity [4]. HA levels in induced sputum 
from patients with COPD were measured and related to local inflammation. HA levels were 
significantly higher in the sputum from patients with COPD than controls [5, 6]. 
That is why HA is considered by modern researchers as one of the markers of inflammation at 
COPD, but there are no researchers about its role like a marker of effectiveness of anti-
inflammatory therapy (AIT) at patients with COPD. 
That is why the aim was to study the diagnostic value of HA at patients with COPD, the role 
of the HA as a marker of the effectiveness of AIT at patients with COPD. 
 
2. Materials and methods 
We have conducted a prospective study which involved 74 patients with COPD (of II and III 
stage), which formed a main group (age – 62,1±0,91 years old: men – 68 (91,9%)), which are 
either accepted therapy variably or did not take AIT which should be taken according to the 
stage of disease.  
At first, all patients went through a screening (visit 1) (n=74), during which we assessed their 
complaints, disease histories, conducted clinical and functional examination, identified the HA 
level as well as adjusted patients’ drug therapy. 
Depending on the degree of bronchial obstruction (BO) patients of the group were divided   
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into two subgroups: subgroup 1 – patients with mild COPD 
course (I and II stage of disease) Which, according to national 
and international guidelines do not require continuous use of 
inhaled glucocorticosteroids (IGCC); subgroup 2 – patients 
who had severe course of COPD (III and IV stage of disease 
which require continuous use of IGCC. 
Further the most part from the patients of the main group (50 
patients) visited us every three months in the following way: 
visit 2 – in 3 months, visit 3 – in 6 months, visit 4 – in 9 
months after their involvement in research after correction of 
the treatment. These patients make main group of dynamic 
observation. 
The control group consisted of 26 healthy individuals (age – 
53,2±2,8 years old).  
Methods included general studies, spirometry, plasma levels of 
HA prior the basic treatment and during basic therapy. 
The COPD clinical diagnoses were formulated in compliance 
with the recommendations of the Order of the Ministry of 
Healthcare of Ukraine №128 from 19.03.2007 [7]. 
The research of the external respiration function (ERF) with a 
characteristic of the main bronchial obstruction indicators 
(forced vital capacity of lungs (FVCL), pulmonary forced 
expiratory volume in 1 minute (FEV1)) was conducted using 
computer spirometry with the help of the Master Screen 
Body/Diff device (“Jager”, Germany). The post-bronchodilator 
test of bronchial obstruction reversibility was made using 400 
mkg of salbutamol. 
The level of HA in plasma was determined by a modified 
ELISA Gold [8]. The total amount of GAGs was assessed by 
optical density of the solution containing the complex formed 
by these polysaccharides with alcyan blue. An important 
feature of the above, the dye is that, depending on the acidity 
of the medium it selectively forms complexes with sulfated 
(acidic environment) or nonsulfated (alkaline) GAGs. We used 
monochromatic light with a wavelength of 480-492 nm. As 
calibration standards used highly clean HA («Sigma», USA). 
Statistical treatment of the research materials was conducted 
using the methods of biometric analysis implemented in the 
EXCEL-2003 (№ 74017-641-9475201-57075), STATISTICA 
6.0 (№ 31415926535897) program packages 9. 
All the examined people gave their consent to clinical 
research.  
 
3. Results 
All the 74 patients were involved in the research in the phase 
of stability of the pathological process; none of them 
demonstrated any clinical signs of infective exacerbation of 
COPD. On the stages of long-term dynamic follow-up (when 
making further visits with biomarkers levels identification) 
none of the patients revealed any clinical signs of infective 
exacerbation of the disease, either. Not a single patient was 
excluded from the research on its various stages for any 
reason.  
On visit 1we found that the level of HA at patients of main 
group was significantly higher than it at patients of the control 
group (Table 1), being increased almost twofold, but in 
subgroups of patients depending on the severity of the disease 
were almost identical. 
Correlations between the HA and the severity of the disease 
has not been determined (r = -0,109; p = 0.355), while direct 
correlation was determined between the level of HA and FEV1 
(post) (Fig. 1). 
 
Тable 1: HA levels in plasma of patients with COPD on visit 1 
 
Groups and subgroups HA, mg/ml р M±m Mediana 
Main group (n=74) 0,27±0,01 0,24 Рm-c=0,000 
subgroup 1 (n=37) 0,28±0,01 0,25 p1-c=0,000 
subgroup 2 (n=37) 0,26±0,01 0,23 p2-c=0,000 p2-1=0,235 
Control group (n=26) 0,15±0,02 0,13  
   Notes: 1. m – main group; 
               2. c – Control group; 
               3. 1, 2 – appropriate subgroups. 
 
 
-0,1 0,0 0,1 0,2 0,3 0,4 0,5 0,6
Гiалуронова кислота (мг/мл)
10
20
30
40
50
60
70
80
90
100
110
ОФ
В1
 по
ст
 Гiалуронова кислота (мг/мл):ОФВ1 пост:   r = 0,2135, p = 0,0677
 
 
Fig 1: Dispersion the HA values in plasma at COPD patients depending on the level of FEV1 (post) 
 
Further observation from one visit to another shows gradually 
decreasing of HA level at patient of main dynamic group (pv2-
V1 = 0,000; pv3-B2 = 0,000; pv4-B3 = 0,001; pv4-B1 = 0,000 by 
Wilcoxon criterion). In a year of regular treatment the level of 
HA was adequate to the control group (Table 2).
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Table 2: HA levels in plasma of patients with COPD during their dynamic observations 
 
Groups and subgroups HA, mg/ml р visit 1 visit 2 visit 3 visit 4 
Main group of dynamic observation (n=50) 0,28±0,01 0,23±0,01 0,20±0,01 0,13±0,01 
Pv1-c=0,000 
Pv2-c=0,001 
Pv3-c=0,036 
Pv4-c=0,388 
subgroup 1d (n=23) 0,29±0,01 0,25±0,01 0,21±0,01 0,13±0,01 
pv1-c=0,000 
pv2-c=0,000 
pv3-c=0,001 
pv4-c=0,436 
subgroup 2d (n=27) 0,27±0,01 0,22±0,01 0,20±0,01 0,13±0,01 
Pv1-c=0,000 
pv2-c=0,007 
pv3-c=0,039 
pv4-c=0,415 
Control group (n=26) 0,15±0,02  
     Notes: 1. m – main group; 
                 2. c – Control group; 
 3. 1, 2 – appropriate subgroups. 
 
In the subgroup of patients was similar dynamic parameter 
(Table 2), while for the subgroup 1d statistical parameters 
were pv2-v1=0,002; pv3-v2 =0,000; pv4-v3=0,001; pv4-v1=0,000 by 
Wilcoxon criterion, and for the subgroup 2d they were pv2-
v1=0,000; pv3-v2=0,004; pv4-v3=0,000; pv4-v1=0,000 by Wilcoxon 
criterion. 
Individual analysis showed that among patients of subgroups 
1d on visit 1 only three patients had HA level below 0,20 
mg/ml, on visit 2 – five patients, on visit 3 – eight patients, on 
visit 4 (after a year of adequate drug therapy) – 20 persons. 
Thus, as a result of our study, diagnostic and prognostic 
significance of such marker of systemic inflammation as HA 
levels can be used for individual assessment of COPD patients 
on stages of their long observations, and assist the physician in 
evaluating the adequacy of the medical treatment of the 
patient. 
 
4. Conclusions 
1. Determination of levels of such marker of systemic like 
HA can be used as parameters for further evaluation of the 
clinical stability of patients during their long-term follow-
up. 
2. The significant decreasing of HA level at patients with 
COPD may be a marker of the effectiveness of AIT. 
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